El-Sayed, W.A.; Alminderej, F.M.; Mounier, M.M.; Nossier, E.S.; Saleh, S.M.; Kassem, A.F.
Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2. Molecules 2022, 27, 2047.
https://doi.org/10.3390/molecules27072047
AMA Style
El-Sayed WA, Alminderej FM, Mounier MM, Nossier ES, Saleh SM, Kassem AF.
Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2. Molecules. 2022; 27(7):2047.
https://doi.org/10.3390/molecules27072047
Chicago/Turabian Style
El-Sayed, Wael A., Fahad M. Alminderej, Marwa M. Mounier, Eman S. Nossier, Sayed M. Saleh, and Asmaa F. Kassem.
2022. "Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2" Molecules 27, no. 7: 2047.
https://doi.org/10.3390/molecules27072047
APA Style
El-Sayed, W. A., Alminderej, F. M., Mounier, M. M., Nossier, E. S., Saleh, S. M., & Kassem, A. F.
(2022). Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2. Molecules, 27(7), 2047.
https://doi.org/10.3390/molecules27072047
